Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience

Purpose: Metastatic pancreatic adenocarcinoma has a very poor prognosis. Although irinotecan, oxaliplatin and leucovorin-modulated fluorouracil (FOLFIRINOX) significantly increases survival in advanced pancreatic cancer, compared to employing only gemcitabine (GEM), toxicities have tempered enthusia...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavanna, Luigi, Stroppa, Elisa Maria, Citterio, Chiara, Mordenti, Patrizia, Di Nunzio, Camilla, Peveri, Silvia, Orlandi, Elena, Vecchia, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498392/
https://www.ncbi.nlm.nih.gov/pubmed/31118666
http://dx.doi.org/10.2147/OTT.S200754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498392/
https://www.ncbi.nlm.nih.gov/pubmed/31118666
http://dx.doi.org/10.2147/OTT.S200754

Ejemplares similares